Synephrine – Kodiac biolabs

Plain-language summaryIntrigue 42 / 100

Synephrine is an alkaloid from bitter orange peel (Citrus aurantium) that became a bestselling thermogenic supplement after the FDA banned ephedra in 2004. Structurally it resembles phenylephrine, but it preferentially activates beta-3 adrenergic receptors over the alpha-1 and beta-1 receptors that drive blood pressure changes. The beta-3 activity stimulates fat oxidation and thermogenesis in adipose tissue, which is the basis of the weight-loss claims. Clinical evidence for actual fat loss is modest at best. Plasma half-life is about two hours. Used as a beta-3-preferring adrenergic agonist in metabolic research and as the workhorse stimulant ingredient in many over-the-counter weight-loss formulas. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

27/100

Outcompeted beta-3 agonist with modest evidence, useful only as a reference standard

Look, synephrine got its moment in the sun after the 2004 ephedra ban, and that moment is over. It’s a phenylethanolamine alkaloid from bitter orange with a preference for beta-3 adrenergic receptors over the alpha-1 and beta-1 activity that got ephedra pulled in the first place. That selectivity profile was genuinely interesting in the supplement context circa 2005. In 2026, it’s a textbook example of a compound the research frontier has lapped.

The mechanism isn’t wrong. Beta-3 adrenergic receptors are real targets expressed in adipose tissue and other metabolic compartments, and agonism there does drive thermogenesis via cAMP-mediated lipolysis. The problem is synephrine does this modestly, and we now have far better tools for studying this receptor system. Mirabegron, a pharmaceutical-grade selective beta-3 agonist with solid PK data and actual receptor selectivity characterization, is the obvious bench choice for any serious beta-3 adrenergic research program. Synephrine’s selectivity is partial at best, its potency is low, and the signal-to-noise ratio for controlled experiments is poor compared to purpose-built probes.

The clinical literature reflects exactly this. Multiple small trials have looked at synephrine for thermogenesis and body weight endpoints. The honest read: effect sizes are small, the data isnt compelling by any rigorous standard, and no serious phase 2 or 3 program is chasing it. The broader adrenergic and metabolic pharmacology space has moved to GLP-1 biology, beta-3 selective drugs with actual selectivity data, and mitochondrial targets with novel mechanisms. Synephrine is watching from the parking lot.

What we don’t like about it as a research compound is the ceiling problem. Even a clean, well-powered synephrine study in 2026 just confirms what’s already known about a mechanism that’s already been characterized in depth. The evidence base is decent by supplement standards (multiple small clinical studies, some methodological replication), but that bar is low and the information value per experiment is low. A landmark paper is not coming out of this compound.

The only scenario where it earns bench time today is narrow: comparative pharmacology where you need a weak beta-3 agonist as a reference alongside something more interesting, or structure-activity work in the phenylethanolamine chemical series. That’s a limited application, and most programs would reach for mirabegron or a custom ligand instead. We score it where it belongs: well-understood, outcompeted, modest evidence, and limited utility for anything a frontier investigator would care about right now.

Novelty: 20
Mechanism promise: 28
In-category differentiation: 22
Evidence quality: 38
Translational signal: 32
Research bench value: 25

Rationale Synephrine’s beta-3 adrenergic selectivity was genuinely interesting post-ephedra but is now thoroughly characterized and outcompeted by purpose-built pharmaceutical probes like mirabegron; clinical evidence exists but effect sizes are small, replication is weak by serious trial standards, and the information yield per experiment is too low for anything on the current research frontier.

Adrenergic agonist (bitter orange alkaloid)

p-Synephrine; a phenylethanolamine alkaloid from Citrus aurantium (bitter orange); a beta-3 adrenergic-preferring agonist used as a thermogenic supplement.

Abstract

Synephrine (p-synephrine, (R/S)-4-[1-hydroxy-2-(methylamino)ethyl]phenol; CAS 94-07-5; molecular formula C9H13NO2; molecular weight 167.21) is a phenylethanolamine alkaloid from Citrus aurantium (bitter orange) and other Citrus species. The compound is a structural analog of phenylephrine (the m-isomer) with a beta-3 adrenergic preference (relative to alpha-1 and beta-1) that distinguishes its pharmacology. The beta-3 activity drives thermogenesis and fat oxidation in adipose tissue, the basis for its supplement use as a weight-loss aid. Synephrine became prominent after the 2004 FDA ban on ephedra (which contained the more potent ephedrine). Clinical evidence for weight-loss effect is modest. Plasma half-life is approximately 2 hours. Used as a beta-3-preferring adrenergic agonist in metabolic research and supplement formulations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-383Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.